PhaseBio Pharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 13:2213:22, 20 August 2022 95.149.241.133 talk 896 bytes +11 No edit summary undo

13 August 2022

• curprev 20:0620:06, 13 August 2022 109.180.50.163 talk 885 bytes +15 No edit summary undo

30 July 2022

• curprev 19:3919:39, 30 July 2022 172.18.0.2 talk 870 bytes +870 Created page with "PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046,..."